Last reviewed · How we verify
Magnogene ® (magnesium)
Magnogene ® (magnesium) is a Mineral supplement Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently FDA-approved for Magnesium deficiency or hypomagnesemia, Magnesium supplementation in patients with inadequate dietary intake.
Magnogene is a magnesium supplement that replaces or maintains magnesium levels in the body to support enzymatic function, muscle and nerve function, and metabolic processes.
Magnogene ® is a small molecule, specifically a type of magnesium oxide, used as an intervention in clinical trials. It has been studied for its potential to alleviate neuropathic pain, as seen in a completed clinical trial (NCT01121653) that investigated its impact on patients with neuropathic pain.
At a glance
| Generic name | Magnogene ® (magnesium) |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Mineral supplement |
| Target | Magnesium ion (Mg2+) |
| Modality | Small molecule |
| Therapeutic area | Nutritional/Metabolic |
| Phase | FDA-approved |
Mechanism of action
Magnesium is an essential mineral cofactor for over 300 enzymatic reactions in the body, including energy production, protein synthesis, and neuromuscular transmission. Magnogene provides bioavailable magnesium to correct deficiency states or maintain adequate serum and intracellular magnesium concentrations. This supports normal cardiac rhythm, muscle contraction, and neurological function.
Approved indications
- Magnesium deficiency or hypomagnesemia
- Magnesium supplementation in patients with inadequate dietary intake
Common side effects
- Diarrhea
- Nausea
- Abdominal cramping
- Hypermagnesemia (in renal impairment)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnogene ® (magnesium) CI brief — competitive landscape report
- Magnogene ® (magnesium) updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI
Frequently asked questions about Magnogene ® (magnesium)
What is Magnogene ® (magnesium)?
How does Magnogene ® (magnesium) work?
What is Magnogene ® (magnesium) used for?
Who makes Magnogene ® (magnesium)?
What drug class is Magnogene ® (magnesium) in?
What development phase is Magnogene ® (magnesium) in?
What are the side effects of Magnogene ® (magnesium)?
What does Magnogene ® (magnesium) target?
Related
- Drug class: All Mineral supplement drugs
- Target: All drugs targeting Magnesium ion (Mg2+)
- Manufacturer: University Hospital, Clermont-Ferrand — full pipeline
- Therapeutic area: All drugs in Nutritional/Metabolic
- Indication: Drugs for Magnesium deficiency or hypomagnesemia
- Indication: Drugs for Magnesium supplementation in patients with inadequate dietary intake
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing